Zynex Q4 2023 Earnings Report
Key Takeaways
Zynex reported a decrease in revenue for Q4 2023 to $47.3 million, a 3% decrease year-over-year, due to a $6.2 million non-recurring write-off. FY 2023 revenue increased 17% year-over-year to $184.3 million. The company's net income for Q4 2023 was $1.2 million, with diluted EPS of $0.04. The Board of Directors has approved an additional $20.0 million of the Company’s common stock.
FY 2023 revenue increased 17% year-over-year to $184.3 million; Q4 2023 revenue decreased 3% year-over-year to $47.3 million due to a $6.2 million non-recurring write-off of slow collecting receivables from a prior period which are booked as a charge against revenue.
FY 2023 net income of $9.7 million; Diluted EPS $0.27; Q4 2023 net income of $1.2 million; Diluted EPS $0.04.
FY 2023 orders increased 43% year-over-year; Q4 orders increased 29% year-over-year, the highest number of orders in Company history for the seventh consecutive quarter.
Company record FY 2023 cash flow from operations of $17.8 million, a 29% year-over-year increase.
Zynex
Zynex
Zynex Revenue by Segment
Forward Guidance
The Company expects 2024 net revenue of at least $227 million, a 23% increase from 2023. Diluted EPS is expected to be at least $0.50 per share, an 85% increase compared to 2023.
Positive Outlook
- Focus on new products.
- Building on our holistic, non-invasive approach to pain management.
- Expect 2024 net revenue to increase approximately 22% compared to 2023.
- Part of our revenue growth will come from more aggressively promoting our bracing line of products as well as traction, cold/post-op and compression products.
- Unique position to deliver solid revenue growth and profitability that allows us to invest in the business and return cash to shareholders at the same time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income